TY  - JOUR
T1  - Evaluation of the relationship between surfactant protein D levels and COVID-19 clinical severity: a case-control study
TT  - Sürfaktan protein D düzeyleri ile COVID-19 klinik şiddeti arasindaki ilişkinin değerlendirilmesi: bir vaka kontrol çalışması
AU  - Koseler, Aylin
AU  - Karslı, Emre
AU  - Sabırlı, Ramazan
AU  - Gören, Tarık
AU  - Kemancı, Aykut
AU  - Karış, Denizhan
AU  - Türkçüer, İbrahim
AU  - Kurt, Özgür
AU  - Bertrand, Philippe
PY  - 2023
DA  - January
Y2  - 2022
DO  - 10.31362/patd.1159512
JF  - Pamukkale Medical Journal
JO  - Pam Med J
PB  - Pamukkale University
WT  - DergiPark
SN  - 1308-0865
SP  - 137
EP  - 147
VL  - 16
IS  - 1
LA  - en
AB  - Purpose: Serum surfactant protein D (SP-D) plays roles in the body such as protection against viral infection,bacterial and fungal clearance, clearance of apoptotic cells and suppression of inflammation. This study aims toexamine the relationship between SP-D level and coronavirus disease (COVID-19) severity.Methods: 80 patients (30 with mild disease and 50 with severe/critical COVID-19), and 50 healthy volunteerswere enrolled in the study. SP-D levels were analyzed by ELISA in serum samples.Results: The median of SP-D was found to be 2.47 (1.67-7.79) ng/ml in mild disease and 5.65 (3.09-16.55) ng/ml in severe/critical disease groups, while 2.89 (10.8-6.24) ng/ml in the healthy controls. The differences in SP-Dlevels between the severe/critical disease group compared to both mild disease and control groups were foundstatistically significant (p=0.007 and 0.001, respectively). ROC analysis showed greater AUC for the serumSP-D levels of the severe/critical COVID-19 patients compared to mild COVID-19 disease patients (AUC=0,691,95% CI=0.56-0,822; p=0.004). Furthermore, SP-D levels were 86% sensitive and 51.6% specific at 2.44 ng/mllevel (p=0.004) to detect severe/critical patients.Conclusion: SP-D levels is useful for COVID-19 patients in the prediction of clinical severity and prognosis.SP-D is a valuable biomarker for predicting the clinical severity and prognosis.
KW  - Serum surfactant protein D
KW  - COVID-19
KW  - pneumonia
KW  - pnömoni
N2  - Amaç: Serum surfaktan protein D (SP-D) vücutta viral enfeksiyona karşı koruma, bakteriyel ve fungal klirens,apoptotik hücrelerin temizlenmesi ve inflamasyonun baskılanması gibi roller oynar. Bu çalışma, SP-D düzeyi ilekoronavirüs hastalığı (COVID-19) şiddeti arasındaki ilişkiyi incelemeyi amaçlamaktadır.Gereç ve yöntem: Çalışmaya 80 hasta (30 hafif hastalığı ve 50 ağır/kritik COVID-19) ve 50 sağlıklı gönüllü dahiledildi. Serum örneklerinde SP-D seviyeleri ELISA ile analiz edildi.Bulgular: SP-D düzeyi ortanca değeri hafif hastalıkta 2,47 (1,67-7,79) ng/ml, ağır/kritik hastalık gruplarında5,65 (3,09-16,55) ng/ml iken, sağlıklı control grubunda 2,89 (10,8-6,24) ng/ml olarak bulundu. Ağır/kritik hastalıkgrubu hem hafif hastalık hem de kontrol grubu ile karşılaştırıldığında SP-D düzeylerindeki farklılıklar istatistikselolarak anlamlı bulundu (sırasıyla p=0,007 ve 0,001). ROC analizi, hafif COVID-19 hastalığı hastalarına kıyaslaşiddetli/kritik COVID-19 hastalarında serum SP-D seviyeleri için eğri altında kalan alan daha yüksek saptandı(AUC=0.691, %95 CI=0,56-0.822; p=0,004). Ayrıca, ağır/kritik hastaları saptamak için SP-D düzeyleri 2,44 ng/ml düzeyinde (p=0,004) %86 duyarlı ve %51,6 özgül saptandı.Sonuç: SP-D seviyeleri, COVID-19 hastaları için klinik şiddeti ve prognozu tahmin etmede faydalıdır. SP-D,klinik şiddeti ve prognozu tahmin etmek için değerli bir biyobelirteçtir.
CR  - 1.	CDC. 2019 Novel Coronavirus, Wuhan, China. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/about/index.html. January 26, 2020; Accessed: January 27, 2020.
CR  - 2.	Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-.19) (Updated 2020 Aug 10). In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/
CR  - 3.	Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 2020;55:102763. doi: 10.1016/j.ebiom.2020.102763.
CR  - 4.	Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433. doi: 10.1016/j.jaut.2020.102433.
CR  - 5.	Mason RJ. Biology of alveolar type II cells. Respirology 2006 ;11 Suppl:S12-15. . doi: 10.1111/j.1440-1843.2006.00800.x.
CR  - 6.	Bernhard W. Lung surfactant: Function and composition in the context of development and respiratory physiology. Ann Anat 2016;208:146-150. doi: 10.1016/j.aanat.2016.08.003.
CR  - 7.	Kishore U, Greenhough TJ, Waters P, et al. Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol Immunol 2006;43:1293-315. doi: 10.1016/j.molimm.2005.08.004.
CR  - 8.	Mori K, Kurihara N, Hayashida S, Tanaka M, Ikeda K. The intrauterine expression of surfactant protein D in the terminal airways of human fetuses compared with surfactant protein Eur J Pediatr 2002;161:431-4. doi: 10.1007/s00431-002-0917-9.
CR  - 9.	Knudsen L, Ochs M, Mackay R, et al. Truncated recombinant human SP-D attenuates emphysema and type II cell changes in SP-D deficient mice. Respir Res 2007;8:70. doi: 10.1186/1465-9921-8-70.
CR  - 10.	Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002;165:378-81. doi: 10.1164/ajrccm.165.3.2107134.
CR  - 11.	Sims MW, Tal-Singer RM, Kierstein S, Musani AI, Beers MF, Panettieri RA, Haczku A. Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study. Respir Res 2008 Jan 28;9:13. doi: 10.1186/1465-9921-9-13.
CR  - 12.	Nakamura K, Kato M, Shukuya T, et al. Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study. BMC Cancer 2017 ;17:302. doi: 10.1186/s12885-017-3285-6.
CR  - 13.	https://www.who.int/publications/i/item/clinical-management-of-COVID-19. Accessed: October 27, 2020.
CR  - 14.	M. Chung, A. Bernheim, X. Mei, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV) Radiology. 2020;295:202-207. doi: 10.1148/radiol.2020200230.
CR  - 15.	Turkish Ministery of Health COVID-19 Diasnosis and Treatment Guideline  Accessed at: https://covid19.saglik.gov.tr/Eklenti/39061/0/COVID19rehberieriskinhastatedavisipdf.pdf
CR  - 16.	Vieira F, Kung J, Bhatti F. Structure, genetics and function of the pulmonary associated surfactant proteins A and D: The extra-pulmonary role of these C type lectins. Ann Anat 2017;211:184-201. doi: 10.1016/j.aanat.2017.03.002.
CR  - 17.	Kong XN, Yan HX, Chen L, et al. LPS-induced down-regulation of signal regulatory protein {alpha} contributes to innate immune activation in macrophages. J Exp Med 2007;204:2719-31. doi: 10.1084/jem.20062611.
CR  - 18.	Schurch D, Ospina OL, Cruz A, Perez-Gil J. Combined and Independent Action of Proteins SP-B and SP-C in the Surface Behavior and Mechanical Stability of Pulmonary Surfactant Films. Biophys J 2010;99(10):3290-9. doi: 10.1016/j.bpj.2010.09.039.
CR  - 19.	LeVine AM, Hartshorn K, Elliott J, Whitsett J, Korfhagen T. Absence of sp-a modulates innate and adaptive defense responses to pulmonary influenza infection. Am J Physiol Lung Cell Mol Physiol 2002;282:L563-72. doi: 10.1152/ajplung.00280.2001.
CR  - 20.	Botas C, Poulain F, Akiyama J, et al.Altered surfactant homeostasis and alveolar type II cell morphology in mice lacking surfactant protein D. Proc Natl Acad Sci U S A. 1998;95:11869-74. doi: 10.1073/pnas.95.20.11869.
CR  - 21.	Ikegami M, Grant S, Korfhagen T, Scheule RK, Whitsett JA.Surfactant protein-D regulates the postnatal maturation of pulmonary surfactant lipid pool sizes. J Appl Physiol (1985) 2009;106:1545-52. doi: 10.1152/japplphysiol.91567.2008.
CR  - 22.	Guillot L, Epaud R, Thouvenin G, et al. New surfactant protein C gene mutations associated with diffuse lung disease. J Med Genet 2009;46:490-4. doi: 10.1136/jmg.2009.066829.
CR  - 23.	Chroneos ZC, Sever-Chroneos Z, Shepherd VL. Pulmonary surfactant: an immunological perspective. Cell Physiol Biochem 2010;25:13-26. doi: 10.1159/000272047.
CR  - 24.	Matthay MA, Ware LB, Zimmerman GA: The acute respiratory distress syndrome. J Clin Invest 2012;122:2731-40. doi: 10.1172/JCI60331.
CR  - 25.	El-Deek SE, Makhlouf HA, Saleem TH, Mandour MA, Mohamed NA. Surfactant protein D, soluble intercellular adhesion molecule-1 and high-sensitivity C-reactive protein as biomarkers of chronic obstructive pulmonary disease. Med Princ Pract 2013;22:469-74. doi: 10.1159/000349934.
CR  - 26.	Takahashi H, Kuroki Y, Tanaka H, et al.Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 2000;162:258-63. doi: 10.1164/ajrccm.162.1.9903014.
CR  - 27.	Nishikiori H, Chiba H, Ariki S, et al. Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis. BMC Pulm Med 2014;14:196. doi: 10.1186/1471-2466-14-196.
CR  - 28.	Gong MN, Wei Z, Xu LL, Miller DP, Thompson BT, Christiani DC. Polymorphism in the surfactant protein-B gene, gender, and the risk of direct pulmonary injury and ARDS. Chest 2004;125:203-11. doi: 10.1378/chest.125.1.203.
CR  - 29.	Leth-Larsen R, Nordenbaek C, Tornoe I, Moeller V, Schlosser A, Koch C, et al. Surfactant protein D (SP-D) serum levels in patients with community-acquired pneumonia. Clin Immunol 2003;108:29-37. doi: 10.1016/s1521-6616(03)00042-1.
CR  - 30.	Francone M, Iafrate F, Masci GM , et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol 2020;30:6808-6817. doi: 10.1007/s00330-020-07033-y.
CR  - 31.	Saito A, Kuronuma K, Moniwa K, Kodama K, Takahashi S, Takahashi H,  Chiba H. Serum surfactant protein A and D may be novel biomarkers of COVID-19 pneumonia severity. Preprint from Research Square. https://doi.org/10.21203/rs.3.rs-29567/v1
CR  - 32.	Kerget B, Kerget F, Koçak AO, Kızıltunç A, Araz Ö, Uçar EY, Akgün M. Are Serum Interleukin 6 and Surfactant Protein D Levels Associated with the Clinical Course of COVID-19? Lung 2020;198:777-784. doi: 10.1007/s00408-020-00393-8.
CR  - 33.	Choreño-Parra JA, Jiménez-Álvarez LA, Ramírez-Martínez G, et al. Expression of Surfactant protein D (SP-D) distinguishes severe pandemic influenza A(H1N1) from COVID-19. J Infect Dis 2021;224:21-30. doi: 10.1093/infdis/jiab113.
UR  - https://doi.org/10.31362/patd.1159512
L1  - https://dergipark.org.tr/en/download/article-file/2586091
ER  -